Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > At least give us news about no news ...

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Dec 17, 2021 12:23pm

122 Views

Post# 34241033

RE:RE:RE:RE:At least give us news about no news ...

Was MArsolais talking about what they will do in phase 1b to find efficacy? I am under the impression they will not be doing three cycles in phase 1a.

jfm1330 wrote: As always, I am alone on my side when it comes to patience and communication. Marsolais already said that they would need to do two more cycles of treatment to confirm any efficacy sign, that they don't want to publish interim efficacy data based on artefacts. They are very early in this process with TH1902 and they want to come out with solid data, not with impressions. Also, patience is required if you invest in biopharma, It's the nature of the beast, most often than not, it takes longer than expected, for results, submissions of NDA/BLA, approvals or rejections.

SPCEO1 wrote: I suspect you are correct about the window now being closed for the remainder of 2021, unless of course they do something, like sign a partnership deal before year-end as they would have to disclose that. Yesterday the CFO assured me they would announce whatever they can as soon as they can, but on the cancer front at least, it sure seems like it will be January before we hear anything. I don't see why they could not give us an update on where things stand but companies prefer to hold info tight to their vest until they have all of the data and can put the most positive spin on it. If they shared something before all the data was in, they may inadvertently highlight a flaw that they could otherwise hide.

I cannot see how an offering would be done before cancer news is out. If they try that, it will not be an encouraging sign for cancer and the stock would likely tank. The prospects for cancer is what is holding the stock up and if they send a signal that they don't have anything in cancer by doing an offering prior to phase 1a results, the market will assume those results are not good.